An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. CEO Bobak Azamian, M.D., Ph.D., will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City on February 8, 2024. The live webcast of the chat will be available on the TARS website, with replays accessible within 48 hours and archived for a limited time.
Positive
None.
Negative
None.
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City at 1:00 p.m. ET on Thursday, February 8, 2024.
A live webcast of the fireside chat can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, which is currently being studied in a Phase 2a clinical trial. In addition, Tarsus is developing TP-04 for the potential treatment of Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. TP-04 and TP-05 are both currently being studied in Phase 2a clinical trials to evaluate safety, tolerability, and proof-of activity.
Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 DNakasone@tarsusrx.com
FAQ
When and where will the CEO of Tarsus Pharmaceuticals, Inc. participate in a fireside chat?
Bobak Azamian, M.D., Ph.D., CEO of Tarsus Pharmaceuticals, Inc., will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City at 1:00 p.m. ET on Thursday, February 8, 2024.
How can the live webcast of the fireside chat be accessed?
The live webcast of the fireside chat can be accessed on the events section of the Tarsus Pharmaceuticals, Inc. website.
Will replays of the fireside chat be available?
Replays of the fireside chat will be available on the Tarsus Pharmaceuticals, Inc. website within 48 hours and will be archived for a limited time.
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
